NO20065051L - Bazedoksifenacetat faste dispersjonsfomuleringer - Google Patents

Bazedoksifenacetat faste dispersjonsfomuleringer

Info

Publication number
NO20065051L
NO20065051L NO20065051A NO20065051A NO20065051L NO 20065051 L NO20065051 L NO 20065051L NO 20065051 A NO20065051 A NO 20065051A NO 20065051 A NO20065051 A NO 20065051A NO 20065051 L NO20065051 L NO 20065051L
Authority
NO
Norway
Prior art keywords
solid dispersion
bazedoxifene acetate
dispersion formulations
acetate solid
bazedoxifene
Prior art date
Application number
NO20065051A
Other languages
English (en)
Norwegian (no)
Inventor
Syed Muzafar Shah
Kadum Abdul Nabi Ali
Christian Luther Ofslager
Mahdi Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065051(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20065051L publication Critical patent/NO20065051L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO20065051A 2004-04-08 2006-11-02 Bazedoksifenacetat faste dispersjonsfomuleringer NO20065051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56045204P 2004-04-08 2004-04-08
PCT/US2005/011678 WO2005099677A1 (en) 2004-04-08 2005-04-07 Bazedoxifene acetate solid dispersion formulations

Publications (1)

Publication Number Publication Date
NO20065051L true NO20065051L (no) 2006-11-07

Family

ID=34965020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065051A NO20065051L (no) 2004-04-08 2006-11-02 Bazedoksifenacetat faste dispersjonsfomuleringer

Country Status (20)

Country Link
US (1) US20050227966A1 (uk)
EP (1) EP1732528A1 (uk)
JP (1) JP2007532557A (uk)
CN (1) CN1942177B (uk)
AR (1) AR048534A1 (uk)
AU (1) AU2005232640B2 (uk)
BR (1) BRPI0509381A (uk)
CA (1) CA2561124A1 (uk)
CR (1) CR8617A (uk)
EC (1) ECSP066912A (uk)
GT (1) GT200500083A (uk)
IL (1) IL178235A0 (uk)
MX (1) MXPA06011685A (uk)
NO (1) NO20065051L (uk)
PA (1) PA8629301A1 (uk)
PE (1) PE20060167A1 (uk)
RU (1) RU2400227C2 (uk)
TW (1) TW200605863A (uk)
UA (1) UA86056C2 (uk)
WO (1) WO2005099677A1 (uk)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738283A (en) * 2005-06-29 2007-10-16 Wyeth Corp Formulations of conjugated estrogens and bazedoxifene
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
US20100016290A1 (en) * 2008-02-11 2010-01-21 Livius Cotarca Amorphous polymorph of bazedoxifene acetate
CN101959856A (zh) * 2008-03-11 2011-01-26 雷迪博士实验室有限公司 来那度胺的制备
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
JP5944514B2 (ja) * 2011-10-14 2016-07-05 アレイ バイオファーマ、インコーポレイテッド 固体分散体
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103845336B (zh) * 2014-03-24 2016-03-09 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬组合物
RU2694832C2 (ru) * 2015-03-10 2019-07-17 Шионоги Инк. Твёрдые дисперсии
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) * 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US20040063692A1 (en) * 2002-06-13 2004-04-01 Wyeth Bazedoxifene treatment regimens
ATE447943T1 (de) * 2005-03-31 2009-11-15 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
TW200738283A (en) * 2005-06-29 2007-10-16 Wyeth Corp Formulations of conjugated estrogens and bazedoxifene
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof

Also Published As

Publication number Publication date
CN1942177B (zh) 2011-05-25
PA8629301A1 (es) 2006-10-13
IL178235A0 (en) 2007-03-08
ECSP066912A (es) 2006-12-20
GT200500083A (es) 2005-10-31
AU2005232640A1 (en) 2005-10-27
RU2400227C2 (ru) 2010-09-27
CR8617A (es) 2007-08-28
RU2006132179A (ru) 2008-05-20
MXPA06011685A (es) 2006-12-14
AU2005232640B2 (en) 2011-07-28
JP2007532557A (ja) 2007-11-15
TW200605863A (en) 2006-02-16
CN1942177A (zh) 2007-04-04
PE20060167A1 (es) 2006-04-20
AR048534A1 (es) 2006-05-03
UA86056C2 (uk) 2009-03-25
WO2005099677A1 (en) 2005-10-27
CA2561124A1 (en) 2005-10-27
US20050227966A1 (en) 2005-10-13
EP1732528A1 (en) 2006-12-20
BRPI0509381A (pt) 2007-09-18

Similar Documents

Publication Publication Date Title
NO20065051L (no) Bazedoksifenacetat faste dispersjonsfomuleringer
TW200738281A (en) Bazedoxifene acetate formulations
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
TW200732349A (en) Anti-OX40L antibodies and methods using same
HK1129581A1 (uk)
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
TW200606149A (en) Crystalline polymorph of bazedoxifene acetate
IS2799B (is) Kladribínefnablöndur til inngjafar um munn
UA86055C2 (uk) Кристалічна форма в базедоксифену ацетату
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
EA201070378A1 (ru) Фармацевтические составы орлистата
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
WO2007022321A3 (en) Substituted indoles and use thereof
TW200716130A (en) Purified form of tanaproget
PL1677818T3 (pl) Stabilne kompozycje wodne zawierające G-CSF
UA85703C2 (en) Crystalline polymorph of bazedoxifene acetate
WO2007073567A3 (en) Compositions and methods of modulating the immune response
ATE364619T1 (de) Tibolonformulierungen
MX2009009178A (es) Bis-fosforatos de bazedoxifeno.
DE602004013542D1 (en) 2-phenylpyran-4-on-derivate als selektive cox-2 inhibitoren
DE60102704D1 (de) Trioxepan verbindungen
UA100984C2 (uk) Антитіла проти nrr notch1 і способи їх застосування

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application